Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.55 |
| ▸ | GLP1R | P43220 | 6/20 | 0.54 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.54 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | EDNRA | P25101 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676260 | 0.90 | EDNRA (0.54) | GLP1RNPBWR1EDNRA | |
| SCHEMBL31439140 | 0.87 | GLP1R (0.58) | GHSRGLP1RNPBWR1EDNRA | |
| SCHEMBL16063027 | 0.87 | GLP1R (0.55) | GHSRGLP1RPTH1RNPBWR1RXFP1 | |
| SCHEMBL29634678 | 0.87 | GLP1R (0.59) | GLP1RPTH1RNPBWR1RXFP1 | |
| SCHEMBL3218493 | 0.86 | EDNRA (0.56) | GHSRNPBWR1EDNRA | |
| SCHEMBL30874388 | 0.86 | GLP1R (0.60) | GLP1RPTH1RNPBWR1RXFP1 | |
| SCHEMBL3124499 | 0.85 | EDNRA (0.55) | GHSRGLP1RPTH1RNPBWR1EDNRA | |
| SCHEMBL30576557 | 0.85 | EDNRA (0.61) | GHSRNPBWR1EDNRA | |
| SCHEMBL30977971 | 0.85 | NPBWR1 (0.59) | GHSRNPBWR1EDNRA | |
| SCHEMBL30874398 | 0.85 | GLP1R (0.62) | GHSRGLP1RPTH1RRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017633-B2 | Administering [3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide; hypertension, hyperlipidemia, hyperuricemia, gout and hypercoagulability | NYCOMED GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | KONINKLIJKE HILIPS ELECTRONICS, N.V. (NL) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | NOS3, PLAT, PTGIS | GHSR 891/4885GLP1R 46/4885PTH1R 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.